| Budget Amount *help |
¥4,010,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2006: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Research Abstract |
1.Development of a novel diagnostic system for uterine cervical carcinoma by quantification of the hWAPL mRNA expression level
Up to now, we are trying to establish the optimum quantification method for the hWAPL mRNA expression level. On the other hand, because HPV E6/E7 oncoproteins induce hWAPL expression, we have developed a novel protocol to determine the subtypes of HPVs infected in cervical samples (Oikawa, et. Al., submitted).
2.Development of a novel molecular targeted therapy of uterine cervical carcinoma
Previously, we have found that hWAPL is one of the promising targets for a gene therapy of uterine cervical cancer. Now, the optimum conditions for the active siRNA dispencing method are under examination.
3.Analysis of physical functions of hWAPL
Our study suggested that unscheduled overexpression of hWAPL disturbs mitosis and cytokinesis, and contributes to tumor progression by induction of chromosomal instability (CIN) (Ohbayashi, Oikawa, et. al., Biochem. Biophys. Res. Commun., 2007, 356 : 699-704). In addition, we found that the hWAPL gene encodes a large number of alternative spliced variants (Oikawa, et. Al., submitted). Although further studies are required, expression pattern of hWAPL variants may be some clinical markers for cervical lesions.
|
